Recently Added
News
The Hoofbeats You Hear May Be a Zebra: Cancer Diagnoses in Ages 18 to 39
At Fox Chase, the Young Adult Cancer Program has been developed as a comprehensive, robust resource to help young adults and their doctors face the challenges of cancer just as someone begins to navigate life’s milestones—finishing school, ...
News
“You must be willing to live and breathe breast cancer.”
Richard Bleicher, MD, FACS, recently appointed Chief of the new Division of Breast Surgery, and a long-term director of the Fox Chase Cancer Center Breast Oncology Fellowship, describes the rigorous training and dedication expected of ...
News
HER2-Targeted Agents: Not Just for Breast Cancer
With 20% of breast cancers driven by alterations to the HER2 gene, inhibiting the expression of this gene has been an objective of researchers and clinicians for decades, and a number of inhibitory therapies have been developed.
News
A New Fellowship For Breast Imaging Leadership
The new fellow will spend nine months on interpreting, screening, and diagnostic procedures, learn how to perform all forms of biopsies using the most advanced techniques; and gain skills to run a breast imaging center.
Video
Breast Cancer Screening Guidelines: What You Should Know
Watch this short video on the three components of breast cancer screening—brought to you by Andrea Porpiglia, MD, MSc, FACS, Assistant Professor, Department of Surgical Oncology at Fox Chase.
News
Adjuvant Olaparib a Win for High-Risk, BRCA-Mutant Early Breast Cancer
Researchers at Fox Chase Cancer Center discuss the benefits of the PARP inhibitor olaparib for women with high-risk, HER2-negative, BRCA-mutant early breast cancer.
News
Fox Chase Cancer Center is the first cancer center in the Northeast to feature a new tumor marker technology—the EnVisio Surgical Navigation System and SmartClip Soft Tissue Marker technology. This advancement will make breast excisional ...
News
Fox Chase Researchers Actively Recruiting for Breast Cancer Immunotherapy Trials
Recognizing the need for further evaluation of immunotherapy for breast cancer treatment, Fox Chase Cancer Center has opened two investigator-initiated trials exploring the use of immunotherapy for triple-negative and HER2-positive breast cancer.
